Across TCGA pan-cancer cohorts, PRAMEF19 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PRAMEF19 data layer compared with 10 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRAMEF19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF19 expression acts as an unfavorable survival marker.
HNSC, PCPG, and KIRC are the cancer types where PRAMEF19 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.